

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 15, 2019**

**AngioDynamics, Inc.**

(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b>  (State or Other Jurisdiction of Incorporation)	<b>000-50761</b>  (Commission File Number)	<b>11-3146460</b>  (IRS Employer Identification No.)
<b>14 Plaza Drive Latham, New York</b>  (Address of Principal Executive Offices)	<b>12110</b>  (Zip Code)	
<b>(518) 795-1400</b>  (Registrant's telephone number, including area code)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

**Securities registered pursuant to Section 12(b) of the Act:**

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.01 per share	ANGO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.07 – Submission of Matters to a Vote of Security Holders.**

(a) The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on October 15, 2019.

(b) Shareholders of AngioDynamics voted on the matters set forth below.

**1. The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2022 Annual Meeting of Shareholders of AngioDynamics and until their respective successors are duly elected and qualified, based upon the following votes:**

<u>Nominee</u>	<u>Votes For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
Kevin J. Gould	32,487,844	690,644	1,549,397
Dennis S. Meteny	32,163,154	1,015,334	1,549,397
Michael E. Tarnoff, MD	32,669,038	509,450	1,549,397

**2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2020 was approved based upon the following votes:**

Votes for approval	34,647,230
Votes against	31,517
Abstentions	49,138

There were no broker non-votes for this item.

**3. The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:**

Votes for approval	32,610,524
Votes against	511,361
Abstentions	56,603
Broker non-votes	1,549,397

(c) Not applicable.

(d) Not applicable.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.  
(Registrant)

Date: October 18, 2019

By: /s/ Stephen A. Trowbridge  
Stephen A. Trowbridge  
Senior Vice President and General  
Counsel

---